Caribou released data suggesting its off‑the‑shelf cell therapy platform produced complete and durable responses in advanced B‑cell lymphoma patients, supporting continued development of donor‑derived CAR‑T matched to patients’ immune profiles. Results reported high overall and complete response rates in a heavily pretreated cohort. Company briefings and conference reports note that durability benchmarks approach those of autologous CAR‑T, a key hurdle for allogeneic approaches. Caribou plans to raise capital to advance pivotal studies and scale manufacturing if clinical comparators hold. The findings reinvigorate investor and industry interest in allogeneic cell therapies that promise faster access and lower cost than patient‑specific products, while underscoring the need for larger controlled trials to confirm safety and long‑term efficacy.